Immunoadsorption can improve cardiac function in transplant candidates with non-ischemic dilated cardiomyopathy associated with diabetes mellitus

Autoantibodies Directed Against the Endothelin A Receptor in Patients With Benign Prostatic Hyperplasia

“…Uncontrolled stimulation of GPCRs by the related GPCR‐AABs is thought to perpetuate pathogenically important downstream effects. Consequently as demonstrated preferentially for patients suffering from cardiovascular diseases, strong benefit has been demonstrated following removal of the GPCR‐AABs .…”

The role of B cells in heart failure and implications for future immunomodulatory treatment strategies

“…69,90,91 However, the long-term benefit is unclear, as cardiac autoantibodies reappear in a proportion of treated patients who eventually may require a heart transplant or a ventricular assist device. 91 This is consistent with the fact that these therapies target the damage-mediating product but not its source. Indeed, eventual disease relapse may be related to the reappearance of anti-cardiac antibodies produced by terminally differentiated B cells.…”

Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti‐PLA2R positive primary membranous nephropathy

“…High serum titers correlate with active disease and low levels with remission. [32][33][34] To our knowledge there has only been 1 published report of immunoadsorption treatment for management of membranous nephropathy and none in the post-anti-PLA 2 R era. 26,27 If a patient relapses, this could be predated by a rise in antibody titers.…”

“…Removal of b1adreno-receptor autoantibodies (b1-AAB) by immunoadsorption in Dilated Cardiomyopathy has shown that only a small minority of patients (0% in the first year and approximately 15%-30% by 3 years) will show an increase in significant b1-AAB autoantibodies. [32][33][34] To our knowledge there has only been 1 published report of immunoadsorption treatment for management of membranous nephropathy and none in the post-anti-PLA 2 R era. In 1999 Esnault et al successfully used immunoadsorption for the treatment of various aetiologies of nephrotic syndrome including 4 patients with membranous nephropathy.…”